[Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer]

Thirty-five patients with non-small cell lung cancer (adenocarcinoma: 15, squamous cell: 15, large cell: 5, Stage I: 3, II: 1, IIIA: 8, IIIB: 5, IV: 18) were treated with combination chemotherapy, CDDP 80 mg/m2 day 1, VDS 3 mg/m2 days 1 & 8, and MMC 8 mg/m2 day 1. This regimen was repeated two times at intervals of four weeks. Sixteen partial responses were observed (response rate of 45.7%), and the median duration of survival for responders was 12.6 +/- 7.5 months and for nonresponders 10.1 +/- 4.8 months. Statistically there was no difference between them, but a survival from the onset of therapy of responders was significantly better (p less than 0.05) than that of non-responders. Toxicity was tolerable with myelosuppression, chemotherapy-induced nausea and vomiting.